Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171492 · ClinicalTrials.gov registry record
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
A clinical trial of Non-small Cell Carcinoma and Nodule Solitary Pulmonary, sponsored by Biodesix.
- Active
- Registry status
- 2,000
- Enrollment target
- 20
- Study locations
NCT04171492: Active study of Non-small Cell Carcinoma and Nodule Solitary Pulmonary, sponsored by Biodesix.
NCT04171492 is a study of Non-small Cell Carcinoma and Nodule Solitary Pulmonary that is active but no longer recruiting, run by Biodesix. The registered enrollment target is 2,000 participants, above the 334-participant average among 5 other Non-small Cell Carcinoma trials with a reported enrollment target (499% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04171492, a study of Non-small Cell Carcinoma and Nodule Solitary Pulmonary, is active but no longer recruiting, sponsored by Biodesix.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
Primary Outcome
Malignant diagnosis through histology/pathology or benign diagnosis through histology/pathology, radiologic stability or radiologic confirmation of nodule resolution
Conditions Studied
Study Locations (20)
North Carolina
- The University of North Carolina - Chapel Hill
- Duke University - Durham
- Southeastern Research Center - Winston-Salem
South Carolina
- Ralph H Johnson VA Medical Center - Charleston
- Medical University of South Carolina - Charleston
- Prisma Health - Greenville
Connecticut
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess - Boston
New York
- Mount Sinai Health System - New York
- Northwell Health - New York
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University - Coulmbus
Colorado
- University of Colorado - Aurora
District of Columbia
- MedStar - Washington D.C.
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2026-12 |
What the registry record for NCT04171492 still lists
NCT04171492 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 334-participant average among 5 other Non-small Cell Carcinoma trials with a reported enrollment target (499% higher).
The record links to 2 conditions, with Non-small Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04171492 names 20 study sites across 13 states, led by North Carolina, South Carolina, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04171492 about?
NCT04171492 is a clinical study titled "Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules". This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
What is the current status of trial NCT04171492?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2020-12-18. Estimated completion is 2026-12.
What conditions does trial NCT04171492 study?
This clinical trial studies the following conditions: Non-small Cell Carcinoma, Nodule Solitary Pulmonary.
Who is sponsoring clinical trial NCT04171492?
This trial is sponsored by Biodesix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04171492 being conducted?
This trial has 20 study locations across Colorado, Connecticut, District of Columbia, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI